[Relationship between endothelial and erectile functions in patients with coronary heart disease]

Klinicheskaia Meditsina
|September 22, 2012
PubMed

Insights

Most men with coronary heart disease (CHD) also experience erectile dysfunction (ED). This study found ED prevalence increases with risk factors like diabetes and obesity, indicating ED is a marker of cardiovascular disease severity.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Men's Health

Background:

  • Coronary heart disease (CHD) is a significant health concern in men.
  • Erectile dysfunction (ED) is a common comorbidity in patients with CHD.
  • The relationship between CHD, ED, and cardiovascular risk factors requires further elucidation.

Purpose of the Study:

  • To investigate the prevalence and characteristics of erectile dysfunction (ED) in men with stable coronary heart disease (CHD).
  • To identify risk factors associated with the presence and severity of ED in this population.
  • To explore the link between ED, endothelial function, and markers of atherosclerotic disease.

Main Methods:

  • Cross-sectional study involving 92 men with stable CHD.
  • Patients were categorized into groups with and without ED.
  • Assessment included clinical evaluation, risk factor analysis, and measurement of endothelium-dependent dilation in brachial and cavernous arteries.

Main Results:

  • A high prevalence of ED (68.5%) was observed in men with stable CHD.
  • ED probability and severity correlated with diabetes mellitus, multifocal atherosclerosis, lipid metabolism disturbances, CHD duration, and body mass index.
  • Impaired endothelium-dependent dilation in brachial and cavernous arteries was noted in ED patients, suggesting compromised vascular function.

Conclusions:

  • Erectile dysfunction is highly prevalent in men with coronary heart disease and serves as a significant indicator of underlying vascular dysfunction.
  • The presence and severity of ED are associated with common cardiovascular risk factors and the extent of atherosclerotic lesions.
  • ED in CHD patients highlights compromised endothelial function and underscores its role as a marker for cardiovascular disease severity.

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...